BMND Stock Overview
A biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Biomind Labs Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.46 |
| 52 Week High | US$1.09 |
| 52 Week Low | US$0.025 |
| Beta | -0.037 |
| 11 Month Change | 15.00% |
| 3 Month Change | 100.00% |
| 1 Year Change | 53.33% |
| 33 Year Change | -71.25% |
| 5 Year Change | n/a |
| Change since IPO | -69.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| BMND | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | -37.8% | -3.6% | 0.5% |
| 1Y | 53.3% | -12.9% | 18.7% |
Return vs Industry: BMND exceeded the Canadian Pharmaceuticals industry which returned -12.9% over the past year.
Return vs Market: BMND exceeded the Canadian Market which returned 18.7% over the past year.
Price Volatility
| BMND volatility | |
|---|---|
| BMND Average Weekly Movement | 150.9% |
| Pharmaceuticals Industry Average Movement | 10.6% |
| Market Average Movement | 8.2% |
| 10% most volatile stocks in CA Market | 17.2% |
| 10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: BMND's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine BMND's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 5 | Alejandro Antalich | www.biomindlabs.com |
Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; and BMND08, a 5-Methoxy-N,N-dimethyltryptamine based candidate that is in Phase II clinical trials for treatment of depression and anxiety in patients with Alzheimer’s-type cognitive impairment. It is also developing new and preclinical drug candidates, including BMND02 for treating fibromyalgia, BMND03 for treating addictive disorders, BMND05 for treating chronic pain, BMND06 for treating inflammatory disorders, and BMND07 for treating major depressive disorder.
Biomind Labs Inc. Fundamentals Summary
| BMND fundamental statistics | |
|---|---|
| Market cap | CA$50.49m |
| Earnings (TTM) | -CA$1.96m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-25.7x
P/E RatioIs BMND overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BMND income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$1.45m |
| Earnings | -US$1.45m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.019 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BMND perform over the long term?
See historical performance and comparison